Medtronic Lowers FY2026 EPS Guidance by $0.12/Share Due to MiniMed Flex Launch Costs and IPO Dilution

summarizeSummary

Medtronic plc revised its fiscal year 2026 non-GAAP EPS guidance downwards to $5.50-$5.54, citing a $157 million charge related to the earlier-than-anticipated FDA clearance of MiniMed Flex and dilution from a MiniMed IPO.

check_boxKey Events

• Revised FY2026 EPS Guidance

  Medtronic lowered its non-GAAP EPS guidance for fiscal year 2026 to a range of $5.50-$5.54, a revision from the previous range of $5.62-$5.66.

• MiniMed Flex FDA Clearance

  The MiniMed Flex insulin pump received FDA clearance several months earlier than anticipated, facilitating earlier commercialization.

• One-Time Charge for R&D Funding

  A $157 million one-time charge is expected in Q4 FY2026, impacting EPS by $0.08 per share, related to payments to Blackstone for MiniMed Flex R&D funding.

• MiniMed IPO Dilution

  The recent IPO of 10% of MiniMed is expected to result in an additional $0.04 per share dilutive impact during Q4 FY2026.

auto_awesomeAnalysis

This 8-K details the reasons behind Medtronic's revised fiscal year 2026 non-GAAP EPS guidance, which was lowered by $0.12 per share. The reduction is primarily driven by a $157 million one-time charge to Blackstone Life Sciences for R&D funding following the earlier-than-anticipated FDA clearance of the MiniMed Flex insulin pump, alongside dilution from a recent MiniMed IPO. While the FDA clearance of a new product is a positive operational development, the immediate financial impact is negative for the current fiscal year. Investors should note that the company's fiscal year 2027 EPS growth guidance remains unchanged, suggesting that these impacts are largely confined to the near term.